Niranib 100 mg (Niraparib) Capsules

Niranib (Niraparib) 100 mg Capsules is an oral targeted anticancer medicine belonging to the PARP inhibitor class. It is primarily used as maintenance therapy in adult patients with certain gynecological cancers who have responded to platinum-based chemotherapy.

Therapeutic Effects:

• Helps delay the progression of ovarian cancer.
• Supports long-term disease control following chemotherapy.
• May prolong progression-free survival in eligible patients.
• Targets cancer cell DNA repair mechanisms, reducing tumor growth.
• Used in recurrent epithelial ovarian cancer management.
• Indicated for fallopian tube cancer maintenance treatment.
• Used in primary peritoneal cancer maintenance therapy.
• Assists in reducing the risk of cancer recurrence in selected patients.
• Provides targeted treatment with convenient oral administration.

Active Ingredient:

• Niraparib Tosylate Monohydrate equivalent to Niraparib 100 mg

Composition:
Each capsule contains Niraparib Tosylate Monohydrate INN equivalent to Niraparib 100 mg along with pharmaceutical-grade inactive ingredients required for capsule formulation and stability.

Pharmacological Class:

• Poly (ADP-ribose) Polymerase (PARP) Inhibitor

Dosage Form:

• Oral Capsule

Strength:

• 100 mg

Recommended Adult Dose:

• The dosage should be determined by a qualified healthcare professional based on the patient's body weight, platelet count, clinical condition, and treatment response.

Administration Instructions:

• Take the capsule exactly as prescribed by your physician.
• Swallow the capsule whole with water.
• Do not crush, chew, break, or open the capsule.
• Can be taken with or without food.
• Try to take the medicine at the same time each day for consistent therapeutic effect.

Missed Dose:

• If a dose is missed, skip the missed dose and take the next scheduled dose at the regular time.
• Do not take a double dose to compensate for a missed dose.

Important Usage Information:

• Regular blood count monitoring may be required during treatment.
• Dose adjustments may be necessary in case of adverse reactions.
• Continue treatment for the duration recommended by the treating oncologist.
• Do not discontinue therapy without medical advice.

Route of Administration:

• Oral Use Only.